Fidelity MSCI Health Care Index ETF

Most Recent

  • uploads///Chart  Revenues
    Earnings Report

    Johnson & Johnson’s 4Q15 Estimates: Revenues Will Fall

    On an annual basis, Johnson & Johnson’s revenues have increased over the past few years following the restructuring of its business segments and strong performance of some of its key products.

    By Mike Benson
  • uploads///Chart  Orencia
    Company & Industry Overviews

    Orencia and Other Brands in 3Q17

    Immunoscience portfolio Orencia, Bristol-Myers Squibb’s (BMY) only immunoscience product, is a fusion protein approved for the treatment of moderate-to-severe rheumatoid arthritis and related issues. The drug prevents further damage to bones and joints. Orencia revenue The above chart compares Orencia sales over the last few quarters. Orencia recorded revenue of $632 million in 3Q17, a growth […]

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson Reports Revenue Growth in 3Q17

    Johnson & Johnson (JNJ) reported 10.3% growth in its revenues to $19.7 billion during 3Q17, as compared to revenues of $17.8 billion in 3Q16.

    By Mike Benson
  • uploads///Chart  Revenues
    Earnings Report

    How Pfizer’s Innovative Health and Essential Health Business Performed in 3Q17

    Pfizer’s Innovative Health segment reported 11% growth in revenues at constant exchange rates for 3Q17, offset by an 11% decline.

    By Mike Benson
  • uploads///Chart  Virology
    Earnings Report

    Bristol-Myers Squibb’s 3Q17 Earnings: Virology Products

    Baraclude’s sales fell ~14% to $264.0 million during 3Q17 compared to $306.0 million during 3Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Merck ahead of 3Q17 Earnings

    Analysts estimate Merck’s gross profit margin to come in at 75.8% for 3Q17, a 0.5% increase as compared to its gross profit margin in 3Q16.

    By Mike Benson
  • uploads///Chart  Dev
    Company & Industry Overviews

    Must-Know Recent Developments for Gilead

    On August 28, 2017, Gilead Sciences entered a definitive agreement to acquire Kite Pharma (KITE) for $180 per share in cash.

    By Mike Benson
  • uploads///Chart  SWR
    Company & Industry Overviews

    Inside Merck’s Segment-Wise Performance in 2Q17

    Merck’s Pharmaceuticals segment contributed ~88.2% of total revenues in 2Q17, reporting $8.76 billion.

    By Mike Benson
  • uploads///Chart  Rev
    Company & Industry Overviews

    Eli Lilly & Co.’s Revenues in 2Q17

    Eli Lilly & Co. (LLY) reported revenues of ~$5.8 billion during 2Q17, reflecting 8.0% growth compared to its revenues in 2Q16.

    By Mike Benson
  • uploads///Chart  Onc
    Company & Industry Overviews

    Bristol-Myers Squibb’s Oncology Products in 2Q17

    Bristol-Myers Squibb (BMY) reported a rise in sales for oncology drugs Opdivo, Empliciti, Sprycel, and Yervoy in 2Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Consumer Segment in 2Q17

    The consumer segment Johnson & Johnson’s (JNJ) consumer segment reported revenue of $3.5 billion in 2Q17, a growth of 1.7% from the revenue of $3.4 billion reported in 2Q16. This figure includes 2.3% growth in operating revenue, and was partially offset by a 0.6% foreign exchange impact. Baby care franchise The baby care franchise reported revenue […]

    By Mike Benson
  • uploads///Chart  International
    Company & Industry Overviews

    How Allergan’s International Segment Performed in 2Q17

    Allergan’s (AGN) international business includes total revenues from the sales of branded products as well as aesthetics products outside the US markets.

    By Mike Benson
  • uploads///Chart  NGC
    Company & Industry Overviews

    Pfizer’s Declining-Revenue Products in 2Q17

    We discussed the products that contribute to the growth of Pfizer’s (PFE) revenues in 2Q17. Let’s now take a look at the products that have impacted revenue growth in 2Q17.

    By Mike Benson
  • uploads///Chart  Development
    Earnings Report

    Eli Lilly’s Major Developments in 2Q17

    Eli Lilly repurchased shares worth $200.0 million and distributed dividends of more than $500.0 million to its shareholders in 2Q17.

    By Mike Benson
  • uploads///Chart  Ratings
    Earnings Report

    Pfizer on the Street: Analyst Recommendations after 2Q17

    As of July 31, 2017, of the 22 analysts tracking Pfizer, ten recommend a “buy” for the stock, while 11 recommend a “hold,” and one recommends a “sell.”

    By Mike Benson
  • uploads///Chart  Ratings
    Earnings Report

    Analysts’ Recommendations for Bristol-Myers Squibb in 2Q17

    Analysts expect Bristol-Myers Squibb’s (BMY) top line to rise 4.4% to ~$5.1 billion in 2Q17. They expect its earnings per share to be $0.74 in the quarter.

    By Mike Benson
  • uploads///Chart  MD
    Earnings Report

    Johnson & Johnson: Medical Devices in 2Q17

    Medical devices segment Johnson & Johnson’s (JNJ) medical devices segment grew ~4.9% to ~$6.7 billion for 2Q17, compared with $6.4 billion in 2Q16. This rise included an operational increase of 5.9%, and was offset by a 1% impact of foreign exchange. Cardiovascular care franchise Cardiovascular care franchise sales rose 11.3% to $523 million for 2Q17. This […]

    By Mike Benson
  • uploads///Chart  Med Dev
    Earnings Report

    Johnson & Johnson’s 2Q17 Estimates: Medical Devices

    Johnson & Johnson’s (JNJ) Medical Devices segment deals with the vision care, cardiovascular care, specialty surgery, orthopedics, surgical care, and diabetes care franchises.

    By Mike Benson
  • uploads///Chart  PFE
    Company & Industry Overviews

    How 2Q17 Is Shaping Up for Pfizer

    A look at Pfizer Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. Pfizer’s portfolio, which comprises the Innovative Health and Essential Health segments, includes various medicines, vaccines, and consumer healthcare products. Stock price performance Pfizer’s stock price has fallen ~2.6% in 2Q17. However, the stock price had risen ~2.3% year-to-date as of July […]

    By Mike Benson
  • uploads///Chart  Revenues
    Company & Industry Overviews

    Merck & Co. Reported 1% Growth in Its 1Q17 Revenues

    Merck & Co. (MRK) reported 1% growth to ~$9.4 billion in its 1Q17 revenues, compared to ~$9.3 billion in 1Q16.

    By Mike Benson
  • uploads///chart_ _a_ _tanezumab
    Company & Industry Overviews

    Tanezumab Receives FDA Fast Track Designation

    Tanezumab is an investigational drug co-developed by Pfizer (PFE) and Eli Lilly (LLY) for pain management in chronic pain related to cancer, lower back pain, and osteoarthritis.

    By Mike Benson
  • uploads///Chart  Adcetris and Opdivo
    Company & Industry Overviews

    Updates on the Adcetris and Opdivo Combination

    Bristol-Myers Squibb and Seattle Genetics are evaluating a combination of Opdivo with Adcetris to treat refractory or relapsed classical Hodgkin Lymphoma.

    By Mike Benson
  • uploads///Chart  Taltz
    Company & Industry Overviews

    How Eli Lilly’s Taltz Performed in Clinical Trials

    On June 15, 2017, Eli Lilly announced data from a study that evaluated the safety and efficacy of Taltz in patients with active psoriatic arthritis.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Akcea Therapeutics’ Volanesorsen: 1Q17 Performance

    Volanesorsen Ionis Pharmaceuticals’s (IONS) volanesorsen is a drug designed to reduce apolipoprotein C-III production and triglycerides in patients with dyslipidemia. Akcea Therapeutics, a wholly owned subsidiary of Ionis, is engaged in pre-commercialization activities for volanesorsen, and will take care of the drug’s commercialization once it is approved by the FDA and the European Commission. The […]

    By Mike Benson
  • uploads///Chart  Revenues
    Company & Industry Overviews

    Eli Lilly & Co.’s Revenues in 1Q17

    Eli Lilly & Co. (LLY) reported 7% growth in its 1Q17 revenues to ~$5.2 billion, compared to ~$4.9 billion in 1Q16.

    By Mike Benson
  • uploads///Chart  Consumers
    Company & Industry Overviews

    How Johnson & Johnson’s Consumer Segment Performed in 1Q17

    Johnson & Johnson’s (JNJ) consumer segment includes the baby care, beauty products, oral care, over-the-counter, women’s health, and wound care franchises.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Close Look at Merck & Co.’s Valuation after 1Q17 Earnings

    Merck stock has risen nearly 16.0% over the last 12 months. Analysts estimate that the stock has a potential to return 10.0% over the next 12 months.

    By Mike Benson
  • uploads///Chart  PGC
    Earnings Report

    Pfizer: Understanding Growth Drivers in 1Q17

    Pfizer’s (PFE) revenues have been driven by growth in the sales of key products including Lyrica, Ibrance, Xalkori, and Xeljanz.

    By Mike Benson
  • uploads///Chart  Val
    Miscellaneous

    Is Eli Lilly & Co.’s Valuation Higher Than Its Peers?

    Over the last year, Eli Lilly’s (LLY) forward PE has traded in the range of 18.9x–25.5x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Do Analysts Expect from Merck’s 1Q17 Earnings?

    Merck and Co. (MRK) will release its 1Q17 earnings on May 2, 2017. Analysts’ estimates show EPS of $0.83 on revenues of $9.25 billion for 1Q17.

    By Mike Benson
  • uploads///chart_ __ _ratings
    Miscellaneous

    Analyst Ratings and Recommendations for Eli Lilly

    As of April 19, 2017, there are 22 analysts tracking Eli Lilly. Sixteen of them have recommended a “buy” for the stock.

    By Mike Benson
  • uploads///Chart  Growth
    Earnings Report

    Johnson & Johnson’s 1Q17 Earnings: Changes in Its Growth Rate

    Foreign exchange rates have had a constant negative impact on JNJ’s growth rate in each quarter, mainly because nearly 48% of its total revenue is reported from sales outside the United States.

    By Mike Benson
  • uploads///Chart  LLY
    Miscellaneous

    Analyzing the Performance of Eli Lilly Stock in 1Q17

    Eli Lilly and Company (LLY) is a US pharmaceutical company dealing with both human pharmaceuticals and animal health.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How BMY’s Virology Segment Performed in 2016

    The Virology segment was Bristol-Myers Squibb’s (BMY) second-largest revenue contributor in 2016. The segment contributed ~24.4% of BMY’s total revenue in the year.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Revenue Trends

    Johnson & Johnson’s (JNJ) top line increased 1.7% to ~$18.1 billion for 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Recent Corporate and Pipeline Developments

    In January 2017, ICU Medical modified its merger agreement with Pfizer to acquire Hospira’s global infusion systems business.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck & Co.’s Valuation after Its 4Q16 Earnings

    On a capital structure–neutral basis, Merck & Co. (MRK) currently trades at ~10.2x. This is much lower than the industry’s average of ~11.6x.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck & Co.’s Profit Margins for 4Q16

    Merck & Co. expects revenues between $38.6 billion–$40.1 billion and EPS between $3.72–$3.87 for fiscal 2017.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Changes in Johnson & Johnson’s Growth Rate in 4Q16

    Johnson & Johnson (JNJ) reported a rise of ~2.3% in its revenue on a constant currency basis in 4Q16 compared to 4Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Can Investors Expect from Eli Lilly’s 4Q16 Earnings?

    Eli Lilly stock has fallen 7.5% in the last 12 months. Wall Street analysts estimate that the stock has the potential to return ~12% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What to Expect from JNJ’s Consumer Healthcare Segment

    Johnson & Johnson’s (JNJ) consumer healthcare segment includes baby care, oral care, skin care, over-the-counter products, women’s health, and wound care franchises.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Pharmaceuticals Segment in 3Q16

    The major blockbuster drugs under Johnson & Johnson’s Immunology franchise are Remicade, Stelara, and Simponi/Simponi Aria.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Januvia and Janumet: An Investor’s Perspective

    Januvia and Janumet are two blockbuster drugs in Merck’s diabetes franchise. These drugs help lower blood sugar level in patients with type-2 diabetes.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Pfizer’s Growth Contributors

    Pfizer saw a 2% rise in Lyrica revenues at $1.24 billion in 3Q16, as compared to $1.22 billion in 3Q15, primarily due to a 12% rise in sales in US markets.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s US Specialized Therapeutics Segment in 3Q16

    During 3Q16, the revenues for the US Specialized Therapeutics segment rose 12.1% to $1.45 billion—compared to $1.30 billion during 3Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer’s 3Q16 Earnings: An Overview

    Pfizer reported an ~8% rise in its top line in its 3Q16 earnings on November 1,surpassing analysts’ estimates for revenues but missing estimates for EPS.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Could Allergan’s Revenues Show Growth in 3Q16?

    Analysts estimate that Allergan’s (AGN) revenues will be ~$3.7 billion for 3Q16, a 9.7% decline in revenues compared to 3Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Merck’s 3Q16 Valuation Cheat Sheet

    PE multiples are widely available and represent what one share can buy for an equity investor. On October 26, 2016, Merck (MRK) was trading at a forward PE multiple of ~16.0x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    How Merck’s Blockbuster Drugs Are Impacting Its Revenue

    Merck & Co. (MRK) has seen the negative revenue impact of lower sales levels for a few of its blockbuster drugs, including Remicade, Cubicin, Zetia, and Vytorin.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    A Look at Johnson & Johnson’s Consumer Segment in 3Q16

    The Consumer segment Johnson & Johnson’s (JNJ) Consumer segment’s revenue fell 1.6% to $3.3 billion between 3Q15 and 3Q16. This fall is due to an operational growth of 0.1%, which was more than offset by a negative currency impact of 1.7%. The currency devaluation in Venezuela impacted worldwide growth by ~1.1% during 3Q16. Baby care […]

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Growth Rate: How Has It Fluctuated?

    Johnson & Johnson’s growth rate As discussed in the previous part of this series, on a constant-currency basis, Johnson & Johnson (JNJ) reported a ~4.3% revenue rise between 3Q15 and 3Q16. The company’s 3Q16 revenue was $17.8 billion, surpassing analysts’ estimate of $17.7 billion. The above graph shows that foreign exchange rates have had a […]

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Consumer Healthcare Segment: 3Q16 Estimates

    Johnson & Johnson’s (JNJ) Consumer Healthcare segment includes baby care, oral care, skin care, over-the-counter products, women’s health, and wound care.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Recent Corporate and R&D Progress for Merck & Co.

    Merck is now focused on developing new products as well as expanding the labels of its existing products. Let’s look at its recent corporate and R&D progress.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Which Products Were Key Contributors to Pfizer’s Revenue Growth?

    Revenue growth drivers Previously we discussed Pfizer’s (PFE) revenues and growth trends. To better understand the factors affecting growth, let’s now explore Pfizer’s product portfolio and pipeline. The key performers in the product portfolio include Lyrica, Ibrance, Xeljanz, and Eliquis from the Innovative Health business. Products with positive growth There were several products that contributed […]

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Johnson & Johnson’s Revenue Trend?

    Johnson & Johnson’s (JNJ) top line increased by 3.9% to ~$18.5 billion for 2Q16. It was driven by an operational growth of 5.3% in revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s US Specialized Therapeutics Key to Future Growth

    During 2Q16, the revenues for US specialized therapeutics rose by 11% to $1.5 billion as compared to $1.4 billion during 2Q15.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Allergan’s Revenue Stream in 2Q16

    Allergan (AGN) reported revenues of $3.7 billion in 2Q16. This converts to over 1.5% revenue growth in 2Q16 as compared to $3.6 billion in 2Q15.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Contributing to Merck’s Growth?

    Merck (MRK) reported 0.6% revenue growth to $9.8 billion during 2Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer Expected to Continue Revenue Growth in 2Q16 Earnings

    Analysts expect Pfizer’s (PFE) 2Q16 revenue to grow ~9.8% to ~$13.0 billion following an increase in the sales of the Prevnar family and the company’s new drugs Xalkori and Xeljanz, among others.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Why Investors Can Expect Operational Growth from Merck in 2Q16

    Analysts expect Merck’s (MRK) revenues for 2Q16 to be around $9,791 million, which is nearly the same as revenues of $9,785 million reported for 2Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Estimates for Johnson & Johnson’s 2Q16 Margins

    Johnson & Johnson’s operating profit margin is expected to improve by ~3.5% to 31.2% in 2Q16 as compared to 27.6% in 2Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s 1Q15 Earnings: Changes in Growth Rate

    Johnson & Johnson 1Q16 revenue was $17.48 billion, at par with analysts’ consensus estimate of $17.49 billion.

    By Mike Benson
  • uploads///ecefafcfffbdebfa
    Company & Industry Overviews

    Market Response to Xalkori’s Label Update

    Observing the changes in Pfizer’s stock price after Xalkori’s label update by the European Commission shows that the stock price rose by ~2.8%.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Xalkori Approved by the European Commission

    Pfizer’s oncology drug Xalkori, also termed Crizotinib, was approved for label expansion and label update by the European Commission on November 25.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Insight on Profile 1014: Phase III Study for Xalkori

    Profile 1014 is the Phase III study for Xalkori, an ALK inhibitor. As per Pfizer’s press release, study was a randomized, and involved 343 patients.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.